Wolverine Stack (BPC-157/TB-500 combination)

BPC-157 + TB-500 | Tissue Repair & Recovery Protocol

Weight: N/A
Chain: N/A
6 studies
2025 latest
3 recent
Well Studied
Dose BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose
Frequency BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
Cycle 4-8 weeks for injury recovery; shorter for maintenance
Storage Lyophilized powder: room temperature acceptable; Reconstituted: 2-8°C refrigerated for both peptides

Community Research

Join others researching Wolverine Stack — share findings, ask questions, and learn from real experiences

Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.

Mechanism of Action

BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.

01 Complementary healing mechanisms
02 87.5% improvement in knee pain patients
03 Reduced inflammation and enhanced cell migration
04 Promotes angiogenesis and reduces scarring

Molecular Data

Molecular Weight
N/A
Chain Length
N/A
Type
Peptide blend
Amino Acid Sequence
N/A

Complex or non-standard sequence format

Research Indications

Tissue Repair
Tendon & Ligament Healing most effective

Both peptides show evidence for accelerated repair; BPC-157 improved Achilles tendon healing in animal models.

Muscle Injury Recovery most effective

BPC-157 demonstrates enhanced muscle regeneration; TB-500 promotes cell migration essential for repair.

Joint Pain & Cartilage most effective

Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4 combination.

Wound Healing
Accelerated Wound Closure effective

TB-500 Phase 2 trials showed approximately one month faster healing in ulcer patients.

Anti-Inflammatory
Inflammatory Cytokine Reduction moderate

Both peptides modulate inflammatory pathways through different mechanisms.

Dosing Protocols

Subcutaneous injection recommended; most studied and effective route.

GoalDoseFrequencyRoute
General Recovery ProtocolBPC-157: 250mcg 2x/day + TB-500: 2mg 2x/weekBPC-157 daily, TB-500 twice weeklySubQ
Intensive Injury RecoveryBPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/weekBPC-157 daily, TB-500 twice weeklySubQ near injury site
Maintenance/Prevention ProtocolBPC-157: 250mcg 1x/day + TB-500: 2mg 1x/weekBPC-157 daily, TB-500 weeklySubQ

Reconstitution Instructions

Materials Needed:
  • BPC-157 vial (5mg)
  • TB-500 vial (2-5mg)
  • Bacteriostatic water
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  1. 1 Reconstitute each peptide separately
  2. 2 BPC-157: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
  3. 3 TB-500: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
  4. 4 Inject slowly along vial wall; swirl gently—never shake
  5. 5 Store reconstituted peptides refrigerated at 2-8°C
  6. 6 Do NOT mix peptides in same syringe unless pre-made blend
  7. 7 Use separate injection sites if administering same day

Interactions

++
Growth Hormone (HGH)
BPC-157 upregulates GH receptors; combined use may accelerate recovery.
synergistic
++
CJC-1295/Ipamorelin
GH secretagogues complement stack by increasing endogenous growth hormone.
synergistic
++
PEG-MGF
MGF activates satellite cells; combined mechanisms may enhance muscle recovery.
synergistic
+
GHK-Cu
Copper peptide promotes collagen; no negative interactions expected.
compatible
~
NSAIDs
BPC-157 shows protective effects against NSAID-induced damage; long-term effects unknown.
monitor
~
Corticosteroids
Steroids may counteract healing; BPC-157 shown to reverse some steroid-induced damage in models.
monitor
~
Anticoagulants
Both peptides promote angiogenesis; monitor for bleeding issues.
monitor
!
Chemotherapy Agents
Angiogenesis promotion could theoretically support tumor growth; contraindicated with cancer history.
avoid

What to Expect

Week 1-2
Possible reduction in acute inflammation and pain at injury sites
Week 2-4
Noticeable improvement in recovery between workouts; reduced soreness
Week 4-6
Significant improvement in chronic injuries; improved joint comfort
Week 6-8
Optimal healing effects; structural improvements in damaged tissues
Post-Cycle
Benefits may persist as healed tissue maintains integrity

Side Effects & Safety

Common Side Effects

  • Not extensively documented in human studies
  • Generally well-tolerated in available research

Stop Signs - Discontinue if:

  • Any unusual lumps, growths, or rapid tissue changes
  • Severe injection site reactions or infections
  • Signs of allergic reaction (rash, swelling, difficulty breathing)
  • Unexpected bleeding or bruising
  • Persistent headaches or vision changes
  • Any symptoms suggesting abnormal growth

Contraindications

  • ANY history of cancer or suspicious growths
  • Active malignancy or concurrent chemotherapy
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • White or off-white lyophilized powder cake indicating proper freeze-drying
  • Crystal clear solution after reconstitution with bacteriostatic water
  • Certificate of Analysis with HPLC purity testing (>98%) and mass spectrometry verification

Warning Signs

  • Minor clumping acceptable if dissolves completely with gentle swirling

Bad Signs

  • Collapsed, yellowed, or powder stuck to vial sides—may indicate degradation from heat
  • Persistent cloudiness or visible particles after reconstitution—indicates contamination or degradation

References

  • Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
    Lee E, Padgett B
    Alternative Therapies in Health and Medicine (2021)

    16 patients, intra-articular injection: Overall 87.5% (14/16) experienced knee pain relief. BPC-157 alone: 91.6% improvement (11/12). BPC-157 + TB4 combination: 75% improvement (3/4).

  • Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
    Vasireddi A, et al.
    HSS Journal (2025)

    36 articles reviewed (544 screened, 1993-2024). Preclinical models showed improvements in muscle tears, tendon ruptures, ligament tears, and fracture healing. Mechanism involves enhanced GH receptor expression and angiogenesis.

  • The Regenerative Peptide Thymosin Beta-4 Accelerates the Rate of Dermal Healing in Preclinical Animal Models and in Patients
    Treadwell T, Kleinman HK, Crockford D, Hardy MA, Goldstein AL
    Annals of the New York Academy of Sciences (2012)

    Two Phase 2 clinical trials of stasis and pressure ulcers showed thymosin beta-4 accelerated wound healing by approximately one month in responsive patients.

  • Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications
    Goldstein AL, Hannappel E, Sosne G, Kleinman HK
    Expert Opinion on Biological Therapy (2012)

    Comprehensive review: thymosin beta-4 promotes cell migration, mobilizes stem/progenitor cells, forms new blood vessels, regenerates tissue, and reduces inflammation, apoptosis, and scar formation.

  • Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocytes Growth
    Staresinic M, Petrovic I, Novinscak T, et al.
    Journal of Orthopaedic Research (2003)

    Rats, 10 mcg/kg i.p. daily, 14 days: BPC-157 fully improved biomechanical properties (load of failure, Young's modulus), functional recovery (Achilles functional index), and histological healing of transected Achilles tendons.

  • Thymosin Beta-4 Accelerates Wound Healing
    Malinda KM, Sidhu GS, Mani H, et al.
    Journal of Investigative Dermatology (1999)

    Rats, full thickness wounds: topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days, with increased collagen deposition and angiogenesis.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.